CNV development in fellow eye more active after first year of anti-VEGF treatment
FORT LAUDERDALE, Fla. – More fellow eyes of patients culled from the CATT developed choroidal neovascularization in the second year of follow-up than in the first, a speaker said.
At 2 years, 20.6% of Lucentis (ranibizumab, Genentech) patients developed CNV in the fellow eye and 16.6% of Avastin (bevacizumab, Genentech) patients developed CNV, according to Maureen G. Maguire, MD, speaking at the Association for Research in Vision and Ophthalmology annual meeting.
At year 1, however, the incidence of CNV in the fellow eye was nearly equal; most of the activity occurred in year 2, she said.
Patients with no signs of CNV at baseline in the Comparison of Age-Related Macular Degeneration Treatment Trials were included (727/1,185; 61%) in the risk patient cohort and were examined in follow-up every 4 weeks.
Whereas at year 1, the incidence of CNV in the fellow eyes of study patients was considered equal between the two drugs, at year 2, there was a 4% less incidence of development of CNV in the fellow eye in Avastin patients versus Lucentis patients, representing a 20% reduction that is not statistically significant, Dr. Maguire said.
Disclosure: Dr. Maguire has no relevant financial disclosures.